Phreesia (PHR) AI Stock Analysis

• Market Cap: $1.59B
• Dividend Yield: N/A
• Average Volume (3M): 591.39K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.73
• Revenue Growth: 16.29%
• EPS Growth: 66.01%
• Country: US
• Employees: 2,082
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.07
• Shares Outstanding: 59,504,270
• 10 Day Avg. Volume: 498,787
• 30 Day Avg. Volume: 591,393
• PEG Ratio: -0.16
• Price to Book (P/B): 5.63
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 62.93
• Enterprise Value/Market Cap: 0.95
• Enterprise Value/Revenue: 0.92
• Enterprise Value/Gross Profit: 5.26
• Enterprise Value/Ebitda: -10.21
• 1Y Price Target: $32.33
• Price Target Upside: 20.63% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 68 Neutral
• Price Target: $29.00 ▲(8.21%Upside)

Phreesia's overall score reflects strong revenue growth and cash generation capabilities. The positive earnings call sentiment further supports this. However, challenges with profitability and valuation concerns due to a negative P/E ratio and lack of dividend yield weigh on the score.

Positive Factors

Client Growth

Total revenue per average healthcare services client rose 6% year over year, indicating positive updates on products and increased wallet share with clients.

Earnings Guidance

The company reported a strong start to fiscal 2026, with largely in-line sales and continued strong operating leverage, which drove a 5% raise to full-year adjusted EBITDA guidance.

Financial Performance

Adj-EBITDA rose 408%, significantly exceeding analyst estimates, and the company revised its adj-EBITDA range upward.

Negative Factors

Market Uncertainty

Concerns around pharma marketing budgets in the current policy environment as well as fears of potential delayed purchasing decisions from providers amid funding and reimbursement uncertainty have weighed a bit on the stock following the initial surge.

Regulatory Risks

There is potential risk to Phreesia’s life sciences product offerings in the event of regulatory changes to direct-to-consumer pharma marketing.

Revenue Growth Concerns

There is a slowdown in network solutions revenue growth, with a decrease to 16% in the quarter compared to 26% in fiscal 2025.

Phreesia Business Overview & Revenue Model

Company Description

Phreesia (PHR) is a healthcare technology company that specializes in providing a comprehensive platform for patient intake and engagement. The company's solutions are designed to streamline the patient intake process, enhance patient communication, and improve the overall experience for both healthcare providers and patients. Phreesia's platform integrates with existing healthcare systems, offering services such as appointment scheduling, patient registration, insurance verification, and payment processing.

How the Company Makes Money

Phreesia generates revenue primarily through a subscription-based model, where healthcare providers pay for access to its platform and services. The company offers various pricing tiers and modules, allowing clients to customize their usage according to their needs. In addition to subscription fees, Phreesia earns money through transaction fees from payment processing services integrated within its platform. The company may also benefit from partnerships with healthcare institutions and technology providers, which can enhance its platform offerings and expand its customer base.

Phreesia Financial Statement Overview

Summary

Phreesia demonstrates strong revenue growth and operational efficiency, as reflected in the income statement. However, profitability remains a challenge with continued net losses. The balance sheet is solid with low leverage, but the negative return on equity highlights profitability issues. Cash flow metrics are improving, indicating a positive cash generation trend. Overall, while Phreesia is growing and managing its cash well, achieving profitability remains a key challenge.

Income Statement

Phreesia has shown consistent revenue growth over the years, with a TTM revenue of $434.5 million, up from $280.9 million in 2023. The gross profit margin remains robust at 66.3% TTM, indicating strong operational efficiency. However, the company is still facing challenges with profitability, as evidenced by the negative net profit margin of -9.8% TTM. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The company's balance sheet shows a healthy equity position with a debt-to-equity ratio of 0.06 TTM, suggesting low leverage and financial risk. The equity ratio stands at 70.5% TTM, indicating a strong equity base. However, the return on equity is negative at -15.1% TTM due to the ongoing net losses, which is a concern for potential investors.

Cash Flow

Phreesia's cash flow statement reveals a positive trajectory, with free cash flow growing significantly, reaching $25.5 million TTM. The operating cash flow to net income ratio is favorable at -1.12 TTM, showcasing the company's ability to generate cash from operations despite net losses. The free cash flow to net income ratio is also positive, which is a promising sign of cash flow health.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	419.81M	356.30M	280.91M	213.23M	148.68M
Gross Profit	284.88M	232.29M	171.64M	131.84M	96.29M
EBITDA	-25.58M	-104.00M	-145.48M	-92.30M	-7.62M
Net Income	-58.53M	-136.88M	-176.15M	-118.16M	-27.29M
Balance Sheet
Total Assets	388.42M	370.33M	370.06M	494.48M	326.67M
Cash, Cash Equivalents and Short-Term Investments	84.22M	87.52M	176.68M	313.81M	218.78M
Total Debt	17.80M	11.98M	9.18M	15.80M	14.32M
Total Liabilities	123.61M	118.88M	82.24M	77.20M	63.36M
Stockholders Equity	264.81M	251.45M	287.82M	417.28M	263.31M
Cash Flow
Free Cash Flow	8.29M	-57.48M	-116.33M	-105.52M	-15.69M
Operating Cash Flow	32.38M	-32.38M	-90.12M	-74.71M	2.89M
Investing Cash Flow	-24.09M	-39.67M	-26.20M	-65.23M	-25.09M
Financing Cash Flow	-11.49M	-17.11M	-20.41M	234.97M	150.66M

Phreesia Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 26.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHR, the sentiment is Positive. The current price of 26.8 is below the 20-day moving average (MA) of 27.70, above the 50-day MA of 26.55, and above the 200-day MA of 24.84, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 53.71 is Neutral, neither overbought nor oversold. The STOCH value of 53.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PHR.

Phreesia Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHR	68 Neutral	$1.59B	―	-15.97%	―	16.29%	66.01%
GDRX	68 Neutral	$1.76B	66.22	4.43%	―	4.35%	―
TXG	65 Neutral	$1.62B	―	-22.03%	―	-0.13%	42.17%
PINC	64 Neutral	$1.74B	36.98	6.05%	3.98%	-17.69%	-10.24%
SDGR	55 Neutral	$1.67B	―	-43.33%	―	22.29%	-32.89%
TDOC	55 Neutral	$1.48B	―	-54.49%	―	-2.54%	-322.03%
Sector *	54 Neutral	€4.56B	17.13	-48.29%	2.92%	15.32%	-7.85%

Phreesia Corporate Events

Phreesia Holds Annual Stockholders’ Meeting

On June 25, 2025, Phreesia, Inc. held its annual stockholders’ meeting where three proposals were voted on. The stockholders elected two directors, Gillian Munson and Mark Smith, M.D., for a three-year term. Additionally, the appointment of KPMG LLP as the independent registered public accounting firm was ratified, and the compensation of named executive officers was approved on a non-binding, advisory basis.

The most recent analyst rating on (PHR) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Phreesia stock, see the PHR Stock Forecast page.